Clearside Biomedical filings document the company's ophthalmology business, common stock structure and formal corporate-status disclosures. Its records include Form 15 notice covering termination or suspension of Exchange Act reporting duties for its common stock, 8-K material-event reports, proxy materials for stockholder votes, and amendments to its certificate of incorporation.
The filing record also covers capital-structure changes, including a one-for-fifteen reverse stock split and reduced authorized common shares, Nasdaq continued-listing matters, royalty and milestone-payment agreements tied to XIPERE and SCS Microinjector technology, operating and financial results, governance procedures and risk-related event disclosure.
Clearside Biomedical, Inc. has ended a prior resale registration and is deregistering any unsold portion of the 3,178,367 shares of common stock that had been registered on a Form S-3 for selling stockholders. The company states that it has terminated the offerings of securities under that registration statement and is removing from registration all securities that remain unsold. This step is an administrative clean-up of an existing shelf registration rather than a new financing or capital-raising transaction.
Clearside Biomedical, Inc. has filed for Chapter 11 bankruptcy and faces delisting from Nasdaq. On November 23, 2025, the company voluntarily filed for relief under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware and will continue operating as a debtor-in-possession while seeking Court approval for various first-day motions to keep its business running. The company’s stated objective in the case is to sell substantially all of its assets to the highest bidder.
On November 24, 2025, Nasdaq notified Clearside that, due to the bankruptcy case and prior noncompliance with the minimum Market Value of Listed Securities requirement of $50,000,000, its common stock will be delisted. Trading on Nasdaq is expected to be suspended at the opening of business on December 1, 2025, after which the shares are expected to trade on the OTC market under the symbol CLSDQ.
Clearside Biomedical filed its Q3 2025 report highlighting tightening liquidity and a strategic review. Cash and cash equivalents were $6.8 million as of September 30, 2025, and management stated these conditions raise substantial doubt about the company’s ability to continue as a going concern. In July, all employees were terminated and transitioned to consulting roles, incurring $2.3 million in severance, while internal R&D was paused during the review.
Quarterly license and other revenue was $201,000 (vs. $1.04 million a year ago). Net loss for Q3 was $6.0 million (vs. $7.7 million). For the nine months, net loss was $18.7 million (vs. $27.0 million). Operating cash use was $16.0 million year-to-date.
The company effected a 1-for-15 reverse stock split on September 12, 2025, and reported 5,233,981 shares outstanding as of November 12, 2025. It amended its royalty sale with HCR, receiving $2.9 million and reducing the cap to $106.5 million. An at-the-market program raised $1.4 million year-to-date. Health Canada approved XIPERE in July 2025; commercialization economics are subject to the royalty sale structure.
Clearside Biomedical, Inc. disclosed that Nasdaq notified the company it was non-compliant with the exchange's minimum bid price rule because the company's common stock traded below $1.00 per share for the prior 30 consecutive business days. The company failed to regain compliance within the standard 180‑calendar day cure period ending on August 6, 2025, and Nasdaq advised on August 11, 2025 that the securities are subject to delisting unless a timely hearing is requested.
Clearside Biomedical, Inc. (CLSD) amended its charter to implement a one-for-fifteen reverse stock split of its common stock and to reduce authorized common shares from 400,000,000 to 26,666,666. The amendment will become effective at 5:00 p.m. Eastern Time on September 12, 2025. Stockholders approved a series of alternate amendments at a Special Meeting on August 29, 2025, and the board selected the specific 1-for-15 split and corresponding authorized share reduction on September 4, 2025. The filing reports these charter changes only; no additional operational, financial, or forward-looking information is provided.
Clearside Biomedical announced a one-for-fifteen reverse stock split and a reduction in authorized common shares. The company will effect a 1-for-15 reverse split of its outstanding common stock and reduce authorized common shares from 400,000,000 to 26,666,666. The certificate amendment implementing these changes becomes effective at 5:00 p.m. Eastern Time on September 12, 2025. Stockholders approved a series of alternate amendments, including the reverse split and authorized-share reduction, at a Special Meeting on August 29, 2025, and the board adopted the specific 1-for-15 split and corresponding reduction on September 4, 2025.
Clearside Biomedical, Inc. disclosed a material transaction in which the seller in a purchase arrangement received $32.5 million. To secure obligations under the Purchase Agreement, the company granted a Pledge Agreement that pledged the seller's capital stock as collateral. The agreement gives the Purchaser Agent the right to foreclose on that pledged stock if certain events occur, creating a potential claim on ownership of the Seller's equity. The filing describes the financing and collateral arrangement but does not provide further financial detail or timing for any enforcement.